Skip to main content
. Author manuscript; available in PMC: 2012 Dec 19.
Published in final edited form as: Mol Cancer Res. 2009 Jun 2;7(6):863–869. doi: 10.1158/1541-7786.MCR-08-0418

Figure 3. ENU-treatment in the presence of MDM2-A leads to a reduction in transformation, does not alter survival, and its expression is stabilized in tumors.

Figure 3

A) Histogram of foci/78.5 cm2 detected after ENU treatment of either wild-type or Mdm2-a MEFs (mean of 3 with standard deviation). (B) Kaplan-Meier survival curve of wild-type (dashed line) and Mdm2-a transgenic (solid line) mice after ENU treatment. There was no significant difference in survival between the two groups (p=0.480). (C) Tumor spectrum in Mdm2-a transgenic mice exposed to ENU and wild-type mice exposed to ENU mice. (D) Western blot analysis of MDM2-A expression in normal tissue (lanes 1–4) and tumor tissue (lanes 5–9) obtained from the lungs of wild-type (lane 1), untreated Mdm2-a transgenic mice (lanes 2–5) and ENU-treated Mdm2-a transgenic mice (lanes 6–9). Elevated MDM2-A expression is observed in all tumor tissue irrespective of whether the tumors arose as a consequence of ENU exposure.